Delivery Order SPE2DB22D2206-SPE2DB25FGT52
Award Date
4/28/25
Potential Completion Date
4/29/25
Potential Value
$78K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,579.81 firm-fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampules, a medication used in the treatment of cystic fibrosis. The award has an ultimate completion date of October 18, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $15,849.83, is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used to treat cystic fibrosis. The contract has a period of performance through February 19, 2025 and is structured as a firm fixed-price delivery order. This award is part of Amerisourcebergen's...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,410.99 firm fixed-price delivery order is for the supply of Pulmozyme, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of July 26, 2024 and was awarded on July 25, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $13,357.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The award is for a delivery order to supply Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used to treat cystic fibrosis. The contract has a firm fixed price and a performance period ending on April 30, 2025. This award is not designated as a set-aside contract, indicating open competition. AmerisourceBergen Drug...
This federal contract award is for the delivery of Pulmozyme, a pharmaceutical product used in the treatment of cystic fibrosis, to the Defense Logistics Agency (DLA). The $14,822.52 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract has a period of performance through December 13, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $60,373.02 firm-fixed-price delivery order is for the supply of Pulmozyme 1 mg/ml ampul, 2.5 ml, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of March 13, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also does...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office division. The $14,465.94 firm fixed-price contract is for the supply of Pulmozyme 1 mg/ml ampules, a medication used to treat cystic fibrosis. The contract has an ultimate completion date of September 30, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple indefinite delivery contracts (IDCs) by the DLA and other federal agencies to...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $34,656.77 firm-fixed-price delivery order is for the supply of Pulmozyme, a medication used to treat cystic fibrosis. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampuls. The contract, valued at $32,686.58, is a firm-fixed-price delivery order with an ultimate completion date of January 19, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $58,616.37, is for the supply of Pulmozyme 1 mg/mL ampules (2.5 mL) to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract is not set aside for any specific business type. AmerisourceBergen...